N-Benzyl-p-toluenesulfonamide
CAS : 1576-37-0
Ref. 3D-FB18542
10mg | Arrêté | ||
25mg | Arrêté | ||
50mg | Arrêté | ||
100mg | Arrêté | ||
250mg | Arrêté |
Informations sur le produit
- 4-Methyl-N-(phenylmethyl)benzenesulfonamideBenzyl(4-toluenesulfonyl)amineN-Benzyl-p-tosylamide
- 4-Methyl-N-(Phenylmethyl)-Benzenesulfonamid
- 4-Methyl-N-(Phenylmethyl)Benzenesulfonamide
- Benzenesulfonamide, 4-methyl-N-(phenylmethyl)-
- Benzyl(4-toluenesulfonyl)amine
- Labotest-Bb Lt00786416
- N-Benzyl-4-Methyl-Benzenesulfonamide
- N-Benzyl-4-methylbenzenesulfonamide
- N-Benzyl-P-Toluenesulfonamid
- N-Benzyl-P-Toluenesulfonamide
- Voir d'autres synonymes
- N-Benzyl-P-Toluenesulphonamide
- N-Benzyl-p-tosylamide
- N-Tosylbenzylamine
- NSC 37123
- p-Toluenesulfonamide, N-benzyl-
N-Benzyl-p-toluenesulfonamide is a calcium antagonist that reversibly binds to calcium ions. It is also known as benzothiazide and is an inotrope and a light exposure regulator. This agent has been shown to have beneficial effects on the cardiac system, such as decreasing myocardial hypertrophy and increasing contractility. N-Benzyl-p-toluenesulfonamide blocks the cardiac L type Ca2+ channel, which leads to an increase in cytosolic Ca2+. The binding of this drug to the regulatory domain of the L type Ca2+ channel has been shown using reconstituted membranes. This drug also inhibits the activity of regulatory filament proteins by binding to their N terminal regulatory domains.